Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of Povetacicept in Autoimmune Cytopenias (RUBY-4)
2023-507067-19-00Phase 2Completed
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Apr 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of povetacicept in immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD) and 1 more (3 cohorts), sponsored by Alpine Immune Sciences, Inc. Primary endpoint: Safety (Adverse Events). Started Apr 2024; status: completed.
02
Drugs
povetacicept
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)cold agglutinin disease (CAD)autoimmune cytopenia
Beyond the preview
Go deeper on 2023-507067-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507067-19-00.